Cherry Creek Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Cherry Creek Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$403K	Hold	770	–	–	0.15%	85
2026 Q2	$382K	Sell	770 -562	-42%	-$249K	0.15%	83
2026 Q1	$595K	Sell	1,332 -68	-5%	-$31.7K	0.26%	58
2025 Q4	$635K	Sell	1,400 -722	-34%	-$311K	0.27%	57
2025 Q3	$831K	Sell	2,122 -986	-32%	-$412K	0.36%	44
2025 Q2	$1.38M	Sell	3,108 -71	-2%	-$32.7K	0.65%	34
2025 Q1	$1.54M	Hold	3,179	–	–	0.8%	30
2024 Q4	$1.28M	Sell	3,179 -143	-4%	-$66.3K	0.63%	32
2024 Q3	$1.54M	Hold	3,322	–	–	0.8%	28
2024 Q2	$1.56M	Buy	3,322 +493	+17%	+$214K	0.81%	28
2024 Q1	$1.18M	Buy	2,829 +1,816	+179%	+$768K	0.64%	32
2023 Q4	$412K	Buy	+1,013	New	+$374K	0.25%	61

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.93B AUM 20.85% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Cherry Creek Investment Advisors's VRTX Position: Q3 2026 in Review

Cherry Creek Investment Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 770 shares worth $403K. The position accounts for 0.15% of the portfolio, ranked #85.

Cherry Creek Investment Advisors first reported a position in VRTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.56M in Q2 2024. 215 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Cherry Creek Investment Advisors held 770 shares of Vertex Pharmaceuticals worth $403K as of Q3 2026.
Cherry Creek Investment Advisors left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
Vertex Pharmaceuticals made up 0.15% of Cherry Creek Investment Advisors's portfolio in Q3 2026, its #85 holding.
Cherry Creek Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
Cherry Creek Investment Advisors's Vertex Pharmaceuticals position peaked at $1.56M in Q2 2024.
215 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Cherry Creek Investment Advisors's 13F filing for Q3 2026, filed 14 Oct 2026.